Longeveron (LGVN) Competitors $0.82 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.84 +0.02 (+3.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. ENTX, DWTX, IZTC, ZSQR, and HYFTShould you buy Longeveron stock or one of its competitors? MarketBeat compares Longeveron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Longeveron include Entera Bio (ENTX), Dogwood Therapeutics (DWTX), Invizyne Technologies (IZTC), Coeptis Therapeutics (ZSQR), and MindWalk (HYFT). These companies are all part of the "pharmaceutical products" industry. LGVN vs. ENTXLGVN vs. DWTXLGVN vs. IZTCLGVN vs. ZSQRLGVN vs. HYFTHow does Longeveron compare to Entera Bio?Entera Bio (NASDAQ:ENTX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Does the media prefer ENTX or LGVN? In the previous week, Longeveron had 14 more articles in the media than Entera Bio. MarketBeat recorded 14 mentions for Longeveron and 0 mentions for Entera Bio. Longeveron's average media sentiment score of 0.93 beat Entera Bio's score of 0.00 indicating that Longeveron is being referred to more favorably in the news media. Company Overall Sentiment Entera Bio Neutral Longeveron Positive Which has more volatility & risk, ENTX or LGVN? Entera Bio has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Which has higher earnings & valuation, ENTX or LGVN? Entera Bio has higher earnings, but lower revenue than Longeveron. Entera Bio is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$40K1,525.82-$11.44M-$0.27N/ALongeveron$1.20M15.91-$22.70M-$1.13N/A Is ENTX or LGVN more profitable? Entera Bio has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Entera Bio's return on equity of -83.31% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Entera BioN/A -83.31% -70.83% Longeveron -1,844.49%-202.41%-140.67% Do analysts recommend ENTX or LGVN? Entera Bio presently has a consensus target price of $9.00, suggesting a potential upside of 625.81%. Longeveron has a consensus target price of $5.50, suggesting a potential upside of 570.57%. Given Entera Bio's higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders & institutionals hold more shares of ENTX or LGVN? 14.1% of Entera Bio shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 10.4% of Entera Bio shares are held by insiders. Comparatively, 11.2% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryEntera Bio beats Longeveron on 9 of the 16 factors compared between the two stocks.How does Longeveron compare to Dogwood Therapeutics?Longeveron (NASDAQ:LGVN) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Do insiders and institutionals have more ownership in LGVN or DWTX? 10.0% of Longeveron shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 11.2% of Longeveron shares are owned by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is LGVN or DWTX more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Dogwood Therapeutics' return on equity of -108.57% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-1,844.49% -202.41% -140.67% Dogwood Therapeutics N/A -108.57%-30.28% Which has more volatility and risk, LGVN or DWTX? Longeveron has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Which has better valuation & earnings, LGVN or DWTX? Longeveron has higher revenue and earnings than Dogwood Therapeutics. Longeveron is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.20M15.91-$22.70M-$1.13N/ADogwood TherapeuticsN/AN/A-$34.26M-$10.60N/A Does the media favor LGVN or DWTX? In the previous week, Longeveron had 2 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 14 mentions for Longeveron and 12 mentions for Dogwood Therapeutics. Longeveron's average media sentiment score of 0.93 beat Dogwood Therapeutics' score of 0.73 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LGVN or DWTX? Longeveron presently has a consensus price target of $5.50, suggesting a potential upside of 570.57%. Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 570.39%. Given Longeveron's stronger consensus rating and higher possible upside, equities analysts clearly believe Longeveron is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryLongeveron beats Dogwood Therapeutics on 10 of the 15 factors compared between the two stocks.How does Longeveron compare to Invizyne Technologies?Longeveron (NASDAQ:LGVN) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Do analysts recommend LGVN or IZTC? Longeveron currently has a consensus target price of $5.50, suggesting a potential upside of 570.57%. Given Longeveron's stronger consensus rating and higher possible upside, equities research analysts plainly believe Longeveron is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LGVN or IZTC more profitable? Invizyne Technologies has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Invizyne Technologies' return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-1,844.49% -202.41% -140.67% Invizyne Technologies N/A N/A N/A Do insiders & institutionals have more ownership in LGVN or IZTC? 10.0% of Longeveron shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer LGVN or IZTC? In the previous week, Longeveron had 14 more articles in the media than Invizyne Technologies. MarketBeat recorded 14 mentions for Longeveron and 0 mentions for Invizyne Technologies. Longeveron's average media sentiment score of 0.93 beat Invizyne Technologies' score of 0.00 indicating that Longeveron is being referred to more favorably in the media. Company Overall Sentiment Longeveron Positive Invizyne Technologies Neutral Which has preferable earnings and valuation, LGVN or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Longeveron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.20M15.91-$22.70M-$1.13N/AInvizyne TechnologiesN/AN/AN/AN/AN/A SummaryLongeveron beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.How does Longeveron compare to Coeptis Therapeutics?Longeveron (NASDAQ:LGVN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Is LGVN or ZSQR more profitable? Coeptis Therapeutics has a net margin of -810.04% compared to Longeveron's net margin of -1,844.49%. Coeptis Therapeutics' return on equity of -92.29% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-1,844.49% -202.41% -140.67% Coeptis Therapeutics -810.04%-92.29%-73.52% Do analysts rate LGVN or ZSQR? Longeveron presently has a consensus price target of $5.50, indicating a potential upside of 570.57%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Longeveron is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor LGVN or ZSQR? In the previous week, Longeveron had 12 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 14 mentions for Longeveron and 2 mentions for Coeptis Therapeutics. Longeveron's average media sentiment score of 0.93 beat Coeptis Therapeutics' score of 0.00 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, LGVN or ZSQR? Coeptis Therapeutics has higher revenue and earnings than Longeveron. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.20M15.91-$22.70M-$1.13N/ACoeptis Therapeutics$1.36M339.59-$11.92M-$2.52N/A Do institutionals and insiders hold more shares of LGVN or ZSQR? 10.0% of Longeveron shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, LGVN or ZSQR? Longeveron has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. SummaryCoeptis Therapeutics beats Longeveron on 9 of the 16 factors compared between the two stocks.How does Longeveron compare to MindWalk?Longeveron (NASDAQ:LGVN) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Is LGVN or HYFT more profitable? MindWalk has a net margin of -66.79% compared to Longeveron's net margin of -1,844.49%. MindWalk's return on equity of -69.37% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-1,844.49% -202.41% -140.67% MindWalk -66.79%-69.37%-39.74% Which has more risk & volatility, LGVN or HYFT? Longeveron has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Does the media favor LGVN or HYFT? In the previous week, Longeveron had 11 more articles in the media than MindWalk. MarketBeat recorded 14 mentions for Longeveron and 3 mentions for MindWalk. Longeveron's average media sentiment score of 0.93 beat MindWalk's score of 0.36 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, LGVN or HYFT? MindWalk has higher revenue and earnings than Longeveron. MindWalk is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$1.20M15.91-$22.70M-$1.13N/AMindWalk$17.59M4.49-$21.69M-$0.20N/A Do insiders and institutionals believe in LGVN or HYFT? 10.0% of Longeveron shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 11.2% of Longeveron shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate LGVN or HYFT? Longeveron currently has a consensus target price of $5.50, indicating a potential upside of 570.57%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 192.40%. Given Longeveron's higher possible upside, equities research analysts clearly believe Longeveron is more favorable than MindWalk.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryMindWalk beats Longeveron on 9 of the 16 factors compared between the two stocks. Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition ExportMetricLongeveronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.08M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-0.7318.7421.2225.65Price / Sales15.91323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book1.197.0910.377.14Net Income-$22.70M$24.45M$3.57B$335.98M7 Day Performance21.31%5.45%6.01%3.56%1 Month Performance-12.74%2.43%3.52%2.54%1 Year Performance-39.24%62.98%34.13%35.05% Longeveron Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron3.3175 of 5 stars$0.82flat$5.50+570.6%-39.2%$19.08M$1.20MN/A20Analyst UpgradeGap DownENTXEntera Bio2.9501 of 5 stars$1.27+3.3%$9.00+608.7%-36.4%$62.51M$40KN/A20Positive NewsDWTXDogwood Therapeutics3.0859 of 5 stars$1.85+8.8%$12.00+548.6%-65.8%$61.79MN/AN/A5IZTCInvizyne TechnologiesN/A$9.55-2.2%N/A-33.4%$59.71MN/AN/A29Gap UpZSQRCoeptis Therapeutics0.0449 of 5 stars$9.59+2.2%N/A-13.7%$59.65M$1.36MN/A2High Trading Volume Related Companies and Tools Related Companies ENTX Alternatives DWTX Alternatives IZTC Alternatives ZSQR Alternatives HYFT Alternatives FLNA Alternatives PYRGF Alternatives ACTU Alternatives IMA Alternatives PDSB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
